Home<About us<Commercial Products

Commercial Products

Type Drug Candidate Indication(s)
  • Preclinical
  • Clinical
    Phase I
  • Clinical
    Phase II
  • Clinical
    Phase III
  • NDA
  • Launched
Monoclonal Antibody TAB014(anti-VEGF) Wet age-related macular degeneration(WAMD)
TAC020(new target) Various solid tumors
Drug Name Indication(s) Product Specification Launched
Pusintin®
(Bevacizumab Injection		 Advanced, metastatic or recurrent non-squamous non-small cell lung cancer (nsNSCLC); metastatic colorectal cancer (mCRC); recurrent glioblastoma multiforme (GBM); epithelial ovarian cancer (OC), fallopian tube cancer or primary peritoneal cancer; cervical cancer (CC); hepatocellular carcinoma (HCC) 100 mg (4 ml)/bottle Approved for listing on November 30, 2021
Tazian®
(Temozolomide Capsule) 		newly diagnosed glioblastoma multiforme, initially combined with radiotherapy, and then as maintenance therapy; glioblastoma multiforme or anaplastic astrocytoma that recurs or progresses after conventional treatment. 20 mg ⅹ 5 capsules/bottle;
100 mg ⅹ 5 capsules/bottle 		Approved for listing on May 31, 2021
Megaxia®
(Megestrol Acetate Oral Suspension) 		anorexia associated with acquired immunodeficiency syndrome (“AIDS”) as well as significant weight loss of AIDS and cancer patients caused by cachexia 125 mg/mL (150 mL/bottle) Approved for listing on May 13, 2021
(Imported from Taiwan, the company has the exclusive agency right in Chinese Mainland, Hong Kong and Macao)

Technology platform for therapeutic monoclonal antibody and ADC drugs

With the assistance of its comprehensive functions covering cell clone screening, cell bank construction screening, process development, pilot-scale studies and commercial manufacturing, we have developed a series of antibodies and antibody-drug conjugates (ADCs) through this platform, such as the monoclonal antibody drugs TAB008 (marketed) and TAB014 (Phase III clinical trial ongoing).

Genetic engineering-based therapeutic technology platform

Integrating anti-tumor immunotherapy, gene therapy and virus therapy, this platform can facilitate R&D and manufacturing of recombinant viral vector systems for tumor targets. The infrastructure located in Suzhou (BSL-2-validated virus production workshop) allows sample manufacturing for pre-clinical studies and Phase I and II clinical trials of oncolytic viruses. The platform plays an important role in the R&D, pilot-scale manufacturing and industrial development of oncology gene therapy technology.